Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

A.M.M. Eggermont; S. Suciu; M. Santinami; A. Testori; W.H. Kruit; J. Marsden; C.J Punt; F. Sales; M. Gore; R. MacKie; Z. Kusic; R. Dummer; A. Hauschild; E. Musat; A. Spatz; U. Keilholz; G. Groenewegen

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Translated title of the contribution: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

A.M.M. Eggermont
, S. Suciu
, M. Santinami
, A. Testori
, W.H. Kruit
, J. Marsden
, C.J Punt
, F. Sales
, M. Gore
, R. MacKie
, Z. Kusic
, R. Dummer
, A. Hauschild
, E. Musat
, A. Spatz
, U. Keilholz
, G. Groenewegen

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
Original language	Undefined/Unknown
Pages (from-to)	117-126
Number of pages	10
Journal	The Lancet
Volume	12
Issue number	372
Publication status	Published - 2008

Cite this

Eggermont, A. M. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Sales, F., Gore, M., MacKie, R., Kusic, Z., Dummer, R., Hauschild, A., Musat, E., Spatz, A., Keilholz, U., & Groenewegen, G. (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. The Lancet, 12(372), 117-126.

@article{6baa936700f14acab62380debdb5e010,

title = "Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial",

author = "A.M.M. Eggermont and S. Suciu and M. Santinami and A. Testori and W.H. Kruit and J. Marsden and C.J Punt and F. Sales and M. Gore and R. MacKie and Z. Kusic and R. Dummer and A. Hauschild and E. Musat and A. Spatz and U. Keilholz and G. Groenewegen",

year = "2008",

language = "Undefined/Unknown",

volume = "12",

pages = "117--126",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "372",

}

Eggermont, AMM, Suciu, S, Santinami, M, Testori, A, Kruit, WH, Marsden, J, Punt, CJ, Sales, F, Gore, M, MacKie, R, Kusic, Z, Dummer, R, Hauschild, A, Musat, E, Spatz, A, Keilholz, U & Groenewegen, G 2008, 'Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial', The Lancet, vol. 12, no. 372, pp. 117-126.

TY - JOUR

T1 - Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

AU - Eggermont, A.M.M.

AU - Suciu, S.

AU - Santinami, M.

AU - Testori, A.

AU - Kruit, W.H.

AU - Marsden, J.

AU - Punt, C.J

AU - Sales, F.

AU - Gore, M.

AU - MacKie, R.

AU - Kusic, Z.

AU - Dummer, R.

AU - Hauschild, A.

AU - Musat, E.

AU - Spatz, A.

AU - Keilholz, U.

AU - Groenewegen, G.

PY - 2008

Y1 - 2008

M3 - Article

SN - 0140-6736

VL - 12

SP - 117

EP - 126

JO - The Lancet

JF - The Lancet

IS - 372

ER -